Chapter 6 - The Clinical TrialThe next four weeks were a descent into a specific kind of hell that only hospitals can construct.
Clara’s condition fluctuated wildly. There were days when the pressure in her brain rose so high she couldn't remember the year, looking at me with a polite, terrified confusion that broke my heart into a thousand pieces. On those days, I would sit by her bed and read her old letters from our college days, rebuilding her memory word by word until her eyes cleared and she whispered, “Ethan.”
Ben and I became a team. The old rivalry, the silent anger between us, dissolved into the shared, desperate labor of keeping a woman alive. He managed her medication logs; I managed the medical specialists I flew in from Boston, Zurich, and New York.
On a cold Tuesday morning in late May, Dr. Aris Thorne, a leading neuro-oncologist from Johns Hopkins, walked into the isolation room. He was carrying a digital file, his serious, dark face drawn into intense lines.
“Mr. Whitaker, Ben,” Dr. Thorne said, closing the door behind him. “We’ve analyzed the genetic sequencing of Clara’s tumor. It contains a specific EGFR mutation that makes it highly resistant to standard chemotherapy.”
My heart plummeted into my stomach. “Meaning?”
“Meaning the current protocol will not stop the growth for more than another three to four weeks,” Thorne explained. He paused, looking at the sleeping girl before looking back at us. “But there is a new targeted molecular therapy—a drug called Gliavance—that is currently in Phase II trials at the Fred Hutchinson Center here in Seattle. It has shown a sixty percent reduction in tumor volume for this exact genetic marker.”
Ben stepped forward, his fists clenching. “Then give it to her. What are we waiting for?”
“It’s not that simple,” Thorne sighed. “The trial is closed to new admissions. The FDA has strict caps on the patient cohort, and because Clara has already undergone a partial resection, she doesn't meet the standard entry criteria. We would need a compassionate-use waiver signed by the pharmaceutical board’s director.”
“Who is the director?” I asked, my corporate instincts instantly taking over, my voice hardening into that familiar, unyielding pitch.
Thorne checked his tablet. “The holding company is a subsidiary of Pendelton Pharma. The board chairman is a man named Arthur Pendelton. He’s based out of Chicago.”
The name hit me like a physical shock. Arthur Pendelton. The corporate lawyer who controlled the international logistics trusts—the same man my father had fought during the shipping wars of 2018. The man who had been a silent partner in Marcus Vance’s shell companies.
The trap hadn't just been built in the past. It was still operating in the present, holding the key to my wife’s survival behind a wall of corporate bureaucracy and old family grudges.
“Get the jet ready, Ben,” I said, turning toward the door, my coat already in my hand.
May you like
Ben looked at me, his eyes wide. “Ethan, what are you going to do?”
“I’m going to buy a life,” I said.
